Bladder Cancer Clinical Trials

None

None

None

Study Evaluating the Efficacy of Synergo Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)

The objectives of the study are to determine the efficacy and safety of Synergo® RITE and mitomycin C (MMC) in the treatment of carcinoma in situ (CIS) non-muscle invasive bladder cancer in adult patients who didn't respond to 2 courses of treatment with Bacillus Calmette-Guérin (BCG) installations. The Synergo® system …

A Phase 3 Randomized Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Therefore, for your type of bladder cancer it is considered experimental. BCG is a live, but weakened, bacterial preparation that has been FDA-approved for use approved for patients with your type of bladder cancer.

Study to Evaluate Imaging Feasibility, Safety and Diagnostic Performance Post Dosing of an Intraoperative Fluorescent Imaging Agent for Detection of Metastatic Lymph Nodes Primary Tumors and Tumor Margins in Patients with Solid Tumors

Part 2: Biopsy-confirmed diagnosis of Stage 2 to 4 or higher HNSCC, breast cancer, colorectal cancer, prostate cancer, bladder cancer, ovarian cancer The study intervention is an IV dose of ONM-100, which is an intraoperative fluorescence imaging agent.